Insights on the Global Peptide Receptor Radionuclide Therapy Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027
The global peptide receptor radionuclide therapy market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The increasing prevalence of neuroendocrine tumors is expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. The establishment of reimbursement policies for Lutathera favors the demand for peptide receptor radionuclide therapy (PRRT).
Moreover, increasing clinical
trials for the new radiopharmaceuticals drugs approval for cancer therapy is
another factor that is expected to fuel the growth of the global peptide
receptor radionuclide therapy (PRRT) market during the forecast period.
Increasing government and private organizations funding for cancer drugs and
therapy development is another major factor expected to propel the market
growth. Moreover, growing manufacturers’ interest in the radiopharmaceutical
and cancer market flourish the growth of the global PRRT market.
To Request a Sample of our Report on Global Peptide Receptor Radionuclide Therapy Market: https://www.omrglobal.com/request-sample/peptide-receptor-radionuclide-therapy-market
The global peptide receptor radionuclide therapy market analysis includes
some of the key market players and research institutes, such as Novartis AG,
ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal
Trials Group, and Toulouse University Hospital, among others.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Novartis
AG, ITM Solucin GmbH, National Institutes of Health, Australasian
Gastro-Intestinal Trials Group, and Toulouse University Hospital, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Peptide Receptor Radionuclide Therapy Market is Available
at: https://www.omrglobal.com/industry-reports/peptide-receptor-radionuclide-therapy-market
Global Peptide Receptor Radionuclide Therapy Market by Segment
By Drug Type
• Lutetium
(Lu-177)-based)
By Disease Indication
• Pancreatic -
Neuroendocrine Tumor
• Gastrointestinal Tract -
Neuroendocrine Tumor
• Others
By Distribution Channel
• Hospital
Pharmacies
• Retail Pharmacies
• Online
Global Peptide Receptor Radionuclide Therapy Market by Regional Analysis
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment